Videos

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.

Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Panelists discuss the emerging potential of KRAS inhibition in metastatic cancer treatment, exploring novel therapies and their promise for patients with KRAS-mutated tumors.

Panelists discuss individualized treatment selection for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on targeted therapies and personalized approaches to improve patient outcomes.

Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell carcinoma.

Alfred L. Garfall, MD, emphasizes the critical importance of the National Institutes of Health funding for biomedical research.

An expert discusses how efficacy and safety data from trials such as METEOR, TIVO-3, TiNivo-2, and LITESPARK-005 guide third line (3L) renal cell carcinoma (RCC) treatment. Differences in trial populations, evolving long-term trends, and prior immune checkpoint inhibitor (ICI) use impact applicability. CONTACT-03 and TiNivo-2 provide key insights, and real-world data and patient-reported outcomes refine clinical decision-making. Community oncologists should critically assess study limitations and evolving evidence when selecting therapy.

An expert discusses how first-line (1L) systemic therapy for unresectable hepatocellular carcinoma (uHCC) has evolved significantly from sorafenib monotherapy to include combination approaches such as atezolizumab plus bevacizumab, which demonstrated superior outcomes in the IMbrave150 trial. Key challenges include underlying liver dysfunction, heterogeneous tumor biology, and managing adverse events while preserving quality of life. Treatment goals focus on extending survival while maintaining liver function and performance status. The shift toward immunotherapy-based combinations has improved outcomes, though patient selection and sequencing strategies remain important considerations in optimizing first-line treatment decisions in clinical practice.

A panelist discusses how, based on the NCCN guidelines for kidney cancer, third-line treatment options for this patient include cabozantinib, lenvatinib plus everolimus, tivozanib, and everolimus monotherapy. Clinical trials and best supportive care remain important considerations at this stage.

An expert discusses the patient case of a 57-year-old woman diagnosed with advanced unresectable hepatocellular carcinoma. The patient presented with abdominal pain, fatigue, and loss of appetite. She also has a history of Crohn disease, which is being controlled with infliximab. The patient also has a history of variceal bleeding and has been treated with antiviral therapy for chronic hepatitis B virus infection.

Uday R. Popat, MD, discusses the rationale behind evaluating itacitinib over other JAK inhibitors for graft-vs-host disease prophylaxis in a phase 2 study.

Palak Dave discusses the potential role of artificial intelligence in improving the accuracy of myelodysplastic syndromes diagnosis.

A panelist discusses how a patient’s initial presentation and molecular profile guide personalized treatment approaches for polycythemia vera (PV), weighing factors such as symptom burden, risk stratification, and genetic markers to optimize therapeutic outcomes.

A panelist discusses how a 67-year-old male smoker presented with frequent headache and dizziness but had an otherwise unremarkable medical history with no splenomegaly.

Panelists discuss how recent clinical trial data and emerging therapeutic options are reshaping the treatment paradigm for myelofibrosis, requiring thoughtful integration of new evidence into current clinical practice guidelines.

Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell malignancies.

Uday R. Popat, MD, discusses a phase 2 trial exploring the use of itacitinib combined with post-transplant cyclophosphamide and tacrolimus to prevent graft-vs-host disease in patients undergoing a myeloablative fractionated busulfan regimen.

Amarnath Challapalli, MBBS, MD, MRCP, FRCR, PhD, discusses some of the most promising findings from the EPIC-A trial of cemiplimab with chemotherapy in treating locally advanced or metastatic penile carcinoma.

Panelists discuss how recent updates in progression free survival data complement secondary endpoints of overall survival, overall response rates, and duration of response to provide a comprehensive picture of treatment efficacy.

Panelists discuss how the latest progression-free survival, overall survival, and overall response rate data presented at ASCO 2025 demonstrate significant advancements in treatment efficacy across multiple tumor types.

Panelists discuss how incorporating both neoadjuvant and adjuvant treatment approaches into clinical trial designs has shown promising improvements in event-free survival outcomes across multiple cancer types.

Panelists discuss how recent clinical data presented at ASCO 2025 showed varying results across primary endpoints including overall survival, progression-free survival, efficacy measures, and safety profiles, with key opinion leaders highlighting implications for current treatment paradigms.

Panelists discuss how to select optimal therapy for a 66-year-old patient with early relapse following autologous stem cell transplantation (ASCT), considering factors such as prior treatment exposure, duration of response, and emerging therapeutic options including cellular therapies.

Panelists discuss how to identify, monitor, and manage delayed toxicities following ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor (CAR) T therapy, including prolonged cytopenias, infections, and neurotoxicity, to optimize long-term patient outcomes and safety.

Marlise R. Luskin, MD, MSCE, discusses the trial of tagraxofusp in BPDCN, which showed high response rates and overall survival.

Alexander Spira, MD, PhD, FACP, discusses the PAPILLON trial, including its methods, design, and rationale as well as new data from the study.

A panelist discusses how patient-reported outcomes and real-world evidence contribute valuable insights into the practical impact of these treatments, complementing traditional efficacy measures and helping inform clinical decision-making in actual practice settings.

The panelist discusses how, expanding clinical trials, biomarker testing, and financial support improves access to emerging EGFR therapies. Novel bispecific antibodies and ADCs may shift treatment. Key insights include resistance monitoring and proactive AE management.

An expert discusses the design and objectives of the Phase 3 PEACE-3 study, which evaluates the combination of enzalutamide (ENZA) and radium-223 (Ra-223) for ARPI-naïve metastatic castration-resistant prostate cancer (mCRPC).

An expert discusses how, in third line (3L) therapy, goals shift from optimal disease control to managing treatment-resistant disease while preserving quality of life. Unlike 2L therapy where significant disease control is still expected, 3L aims for modest clinical benefit, symptomatic relief, and stabilizing disease progression. Treatment choices now heavily prioritize tolerability, patient preferences, and palliative considerations.